Scancell Holdings Plc Grant of European patent for Moditope platform
May 23 2018 - 2:01AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
23 May 2018
23 May 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell announces grant of European patent for its Moditope(R)
immunotherapy platform
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, confirms that following its
announcement on 9 February 2018, the European Patent Office will
grant a European Patent for the Company's Moditope(R) immunotherapy
platform with effect from 13 June 2018.
The patent will provide broad protection for the Company's
pipeline of Moditope(R) vaccines, including any citrullinated
epitopes for the treatment of cancer, in all major European
territories including: Austria, Belgium, Switzerland, Germany,
Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy,
Netherlands, Norway, Poland, Portugal, Sweden and Turkey.
Counterparts to this patent have been filed in Australia, Brazil,
Canada, China, Hong Kong, Japan, South Korea, South Africa and the
US.
Professor Lindy Durrant, Chief Scientific Officer of Scancell,
commented:
"This is a key patent for Scancell and endorses our work in
identifying a new class of cancer vaccine capable of inducing
potent immune responses to stress-induced post-translational
modifications (siPTM), in this case, through citrullination of
cellular proteins. We are now well positioned to develop a pipeline
of new Moditope(R) therapies with the potential to address the
unmet need across a broad range of hard to treat cancers including
ovarian, triple negative breast cancer and sarcoma."
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4 T cells which overcome the immune suppression induced by
tumours, allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAFSAALSPEAF
(END) Dow Jones Newswires
May 23, 2018 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024